Publicacions
El coneixement generat a IrsiCaixa es comparteix amb la comunitat científica a través de la publicació d’articles a revistes científiques d’alt impacte.
Safety and immunogenicity of PHH-1V booster against SARS-CoV-2 variants, including omicron subvariants: Results from a phase IIb open-label extension study.
A human-ACE2 knock-in mouse model for SARS-CoV-2 infection recapitulates respiratory disorders but avoids neurological disease associated with the transgenic K18-hACE2 model.
In danger: HIV vaccine research and development in Europe.
Utilizing HIV Proviral DNA to Assess for the Presence of HIV Drug Resistance.
Long-lasting antibody B-cell responses to SARS-CoV-2 three years after the onset of the pandemic.
Omics for searching plasma biomarkers associated with unfavorable COVID-19 progression in hypertensive patients.
SARS-Cov-2 vaccination strategies in hospitalized recovered COVID-19 patients: a randomized clinical trial (VATICO Trial).
Post-vaccination IgG4 and IgG2 class switch associates with increased risk of SARS-CoV-2 infections.
Doravirine/islatravir (100/0.75 mg) once-daily compared to bictegravir/emtricitabine/tenofovir alafenamide as initial HIV-1 treatment: 48-week results from a phase 3, randomized, controlled, double-blind, non-inferiority trial.
Therapeutic response to an empirical praziquantel treatment in long-staying sub-Saharan African migrants with positive Schistosoma serology and chronic symptoms: a prospective cohort study in Spain.